ArticleAnnals of surgical oncology2026
Prognostic Value of a Novel Staging System Integrating Lymph Node Station Number and Tumor Regression Grade for Esophageal Cancer Following Neoadjuvant Chemoradiotherapy.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Methodological Considerations on Prognostic Modeling in Esophageal Cancer: Commentary on Liu et al. (2026).Annals of surgical oncology · 2026Article
- Reply to: "Methodological Considerations on Prognostic Modeling in Esophageal Cancer-Commentary on Liu et al. (2026)".Annals of surgical oncology · 2026Article
- A pathological classification for predicting recurrence and guiding adjuvant therapy in esophageal squamous cell carcinoma following neoadjuvant immunochemotherapy: a two-center cohort study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to evaluate the prognostic value of tumor regression grade (TRG) in patients with esophageal cancer after neoadjuvant therapy and to validate the prognostic value of a novel TRG system (nTRG) system including the number of metastatic lymph node stations (S system) in patients with esophageal cancer after neoadjuvant therapy.
methodA total of 514 patients were enrolled in the study cohort, and survival differences between categories of the TRG or S system were tested using the Kaplan-Meier (KM) method and log-rank, with the former graded according to College of American Pathologists criteria. The nTRG system was developed by combining the two systems. We compared the discrimination, accuracy, and clinical value of the current American Joint Committee on Cancer (AJCC) post-neoadjuvant staging system (ypTNM) with the nTRG, which integrates TRG and novel metastatic lymph node station number.
resultsIn the training cohort, the discrimination, accuracy, and clinical value of nTRG staging groups were better than those of the ypTNM staging groups, which is reflected in the higher C-index and decision curve analysis values. Results were similar in the validation cohort. Multivariate analysis showed that nTRG stage (P < 0.001), smoking (P = 0.02), and recurrence (P < 0.001) were independent prognostic factors.
conclusionThe nTRG staging system demonstrates superior predictive efficacy to the AJCC ypTNM staging system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.